logo

For the Inventor, By the Inventor

Zofingen, Switzerland

Ludwig Zirngibl

USPTO Granted Patents = 11

Average Co-Inventor Count = 2.9

ph-index = 5

Forward Citations = 57(Granted Patents)


Company Filing History:

goldMedal11 out of 42 
 
Siegfried Aktiengesellschaft
 patents

Years Active: 1976-1987

Loading Chart...
11 patents (USPTO):Explore Patents
1. 4668786 - P-fluorobenzoyl-piperidino alkyl theophylline derivatives (1987-05-26),
2. 4603204 - Theophylline derivatives (1986-07-29),
3. 4554356 - Method for production of imidazolyl vinyl ethers (1985-11-19),
4. 4474956 - Process for the preparation of (1984-10-02),
5. 4330545 - Heterocyclic imidazolyl vinyl ethers and use of same as fungicides or (1982-05-18),
6. 4210657 - Aryl imidazolyl vinyl ethers and processes for using same (1980-07-01),
7. 4210656 - Imidazolyl vinyl ethers and process for preparing same (1980-07-01),
8. 4204998 - N-Amino indole derivatives having pharmacological activity (1980-05-27),
9. 4177350 - Imidazole ethyl oxyalkoxy derivatives and thio analogues thereof (1979-12-04),
10. 4131608 - Thioethers (1978-12-26),
11. 3947584 - Novel indolyl alkyl amines, method of producing same, and their use as (1976-03-30),

Title: Ludwig Zirngibl: Innovator in Theophylline Derivatives

Introduction

Ludwig Zirngibl is a notable inventor based in Zofingen, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the development of new derivatives of theophylline. With a total of 11 patents to his name, Zirngibl's work has had a considerable impact on medical science.

Latest Patents

Zirngibl's latest patents include innovative compounds such as P-fluorobenzoyl-piperidino alkyl theophylline derivatives. These new derivatives exhibit various properties, including histamine-serotonin-bradykinin antagonistic, anti-anaphylactic, and β-adrenergic stimulating effects. Another significant patent involves theophylline derivatives characterized by specific chemical formulas, which also demonstrate similar beneficial properties.

Career Highlights

Zirngibl is currently associated with Siegfried Aktiengesellschaft, a company known for its focus on pharmaceutical development. His work has been instrumental in advancing the understanding and application of theophylline derivatives in medical treatments.

Collaborations

Throughout his career, Zirngibl has collaborated with esteemed colleagues such as Kurt Thiele and Johanna Fischer. These partnerships have fostered a collaborative environment that enhances innovation and research in the pharmaceutical field.

Conclusion

Ludwig Zirngibl's contributions to the development of theophylline derivatives highlight his role as a key innovator in pharmaceuticals. His patents reflect a commitment to advancing medical science and improving therapeutic options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…